<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-66555" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Allergic Bronchopulmonary Aspergillosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>SISODIA</surname>
            <given-names>JITENDRA</given-names>
          </name>
          <aff>M.S University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bajaj</surname>
            <given-names>Tushar</given-names>
          </name>
          <aff>University of Chicago</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>JITENDRA SISODIA declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tushar Bajaj declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-66555.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Allergic bronchopulmonary aspergillosis (ABPA) is a common fungal infection in uncontrolled asthmatics, cystic fibrosis patients, and immunocompromised patients. Early diagnosis and rapid implementation of proper management are critical to prevent complications and/or disease progression. Diagnosis centers around classic clinical manifestations, radiographic findings, and immunological findings. This activity describes the etiology, evaluation, and management of allergic bronchopulmonary aspergillosis and highlights the role of the interprofessional team in caring for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of allergic bronchopulmonary aspergillosis.</p></list-item><list-item><p>Describe the clinical and imaging modalities used to diagnose allergic bronchopulmonary aspergillosis.</p></list-item><list-item><p>Explain how to educate high-risk patients on the prevention of allergic bronchopulmonary aspergillosis.</p></list-item><list-item><p>Explain the importance of improving coordination amongst the interprofessional team to enhance the delivery of care for patients with allergic bronchopulmonary aspergillosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=66555&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=66555">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-66555.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Allergic bronchopulmonary aspergillosis (ABPA) is a fungal infection of the lung due to a hypersensitivity reaction to antigens of <italic toggle="yes">Aspergillus fumigatus</italic> after&#x000a0;colonization into the airways. Predominantly it affects patients with bronchial asthma and those having cystic fibrosis. It characteristically presents with bronchospasm, pulmonary infiltrates, eosinophilia, and immunologic evidence of allergy to the antigens of <italic toggle="yes">Aspergillus</italic> species.<xref ref-type="bibr" rid="article-66555.r1">[1]</xref><xref ref-type="bibr" rid="article-66555.r2">[2]</xref></p>
      </sec>
      <sec id="article-66555.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Aspergillus species are molds that are present ubiquitously in the environment, especially in the organic matter. There are over 100 species worldwide, but most of the illness is caused by Aspergillus fumigatus, Aspergillus niger, Aspergillus flavus, and Aspergillus clavatus. An infection by Aspergillus species causes a broad spectrum of illnesses in humans and depends on the immune status of the host, ranging from hypersensitivity reactions to direct angioinvasion.</p>
        <p>Aspergillus fumigatus is the most common ubiquitous airborne fungus causative organism for ABPA.<xref ref-type="bibr" rid="article-66555.r3">[3]</xref>Aspergillus conidia, because of its small diameter (2 to 3 micrometers), easily reach the pulmonary alveoli and deposits there.</p>
        <p>ABPA affects people who are asthmatic or have cystic fibrosis and are allergic to Aspergillus. The thick mucus in the airways of these patients makes it difficult to clear up the Aspergillus spores when inhaled. Genetic association:&#x000a0;HLA-DR molecules DR2, DR5, and possibly DR4 or DR7 contribute to susceptibility; whereas, HLA-DQ2 contributes to resistance, and a combination of these may determine the outcome of ABPA in CF and asthma.<xref ref-type="bibr" rid="article-66555.r4">[4]</xref><xref ref-type="bibr" rid="article-66555.r5">[5]</xref></p>
      </sec>
      <sec id="article-66555.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Allergic bronchopulmonary aspergillosis commonly presents in the third to fifth decade of life. It is also common in children. It&#x000a0;usually found in severe asthmatics and patients with cystic fibrosis.<xref ref-type="bibr" rid="article-66555.r3">[3]</xref><xref ref-type="bibr" rid="article-66555.r6">[6]</xref></p>
        <p>Allergy to Aspergillus, as shown by a positive skin prick test to Aspergillus antigen, is present in almost 25% asthmatics and 50% of cystic fibrosis patients, but ABPA is not that much prevalent. The prevalence of ABPA in asthma and cystic fibrosis is&#x000a0;about 13% and 9%, respectively.<xref ref-type="bibr" rid="article-66555.r7">[7]</xref>&#x000a0;Worldwide, more than 4 million people are affected by ABPA.<xref ref-type="bibr" rid="article-66555.r8">[8]</xref></p>
        <p><italic toggle="yes">A. fumigatus</italic> is the most common organism that causes ABPA, and the fungus&#x000a0;requires&#x000a0;dead organic matter to survive. The highest incidence of the infection is known to be in the winter season around the world (secondary to fallen leaves).</p>
      </sec>
      <sec id="article-66555.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of allergic bronchopulmonary aspergillosis remains incompletely understood.<xref ref-type="bibr" rid="article-66555.r9">[9]</xref>&#x000a0;A. fumigatus&#x000a0;spores that get inhaled in sufficient quantities behave as allergens. Normally a low level of IgG against fungal antigens in the circulation and the low antifungal secretory IgA in bronchoalveolar fluid suggest that healthy individuals can effectively eliminate fungal spores.<xref ref-type="bibr" rid="article-66555.r10">[10]</xref><xref ref-type="bibr" rid="article-66555.r11">[11]</xref>&#x000a0;In contrast, exposure of atopic individuals to fungal spores or mycelial fragments results in the formation of IgE and IgG antibodies.</p>
        <p>Th2 cells (Helper T cells) play an essential role in the hypersensitivity reaction caused by the <italic toggle="yes">A. fumigatus</italic> antigen. It manifests as&#x000a0;IgE production, eosinophilia, mast cell degranulation, and bronchiectasis.<xref ref-type="bibr" rid="article-66555.r8">[8]</xref></p>
        <p><italic toggle="yes">A. fumigatus</italic> proteases release proinflammatory cytokines, such as IL-8, which causes epithelial cell damage and disruption of protective barriers, which triggers the hypersensitivity reaction. It also releases cytokines interleukin (IL)-4, IL-5, and IL-13, which increases blood and airway eosinophils as well as&#x000a0;IgE.</p>
        <list list-type="bullet">
          <list-item>
            <p>Immunocompetent individuals easily eliminate <italic toggle="yes">Aspergillus</italic> conidia from the airway by the innate immune system mechanisms; therefore, there are no manifestations of pulmonary fungal infections.&#x000a0;If isolated in respiratory secretions like sputum or bronchoalveolar lavage, then it only reflects colonization, not an infection.</p>
          </list-item>
          <list-item>
            <p>Immunocompromised individuals do not eliminate <italic toggle="yes">Aspergillus</italic> conidia due to host immune defense imbalance; therefore, they&#x000a0;colonize&#x000a0;airways and germinate into somatic hyphae that stimulate a chronic allergic inflammatory response that results in tissue injury, which ultimately leads to the clinical features of ABPA.<xref ref-type="bibr" rid="article-66555.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>In atopic individuals (asthmatics), cystic fibrosis patients, and in patients with cavitary lung diseases, inhalation of Aspergillus fumigatus spores triggers an IgE-mediated&#x000a0;hypersensitivity response in the respiratory tract that causes respiratory symptoms like cough with expectoration and breathlessness.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-66555.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathologically, there is&#x000a0;chronic bronchial inflammation, eosinophilia (leading&#x000a0;to the development of an area of parenchymal scarring), airway remodeling, and bronchiectasis. Bronchi may show impacted mucus plug containing fungal hyphae, fibrin, Charcot-Leyden crystals, Curschmann spirals. The dichotomous branching of hyphae occurs at 45-degree angles.<xref ref-type="bibr" rid="article-66555.r8">[8]</xref></p>
      </sec>
      <sec id="article-66555.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <list list-type="bullet">
          <list-item>
            <p>Allergic bronchopulmonary aspergillosis occurs primarily in patients with asthma or cystic fibrosis.</p>
          </list-item>
        </list>
        <p>Clinical presentation<xref ref-type="bibr" rid="article-66555.r7">[7]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>History of recurrent episodes of wheezing with radiological evidence of patchy fleeting pulmonary infiltrates and bronchiectasis.&#x000a0;Wheezing is not always evident, and some patients present with asymptomatic pulmonary consolidation.</p>
          </list-item>
          <list-item>
            <p>History of uncontrolled asthma with increased frequency and severity despite optimum asthma medications.</p>
          </list-item>
          <list-item>
            <p>History of cystic fibrosis.</p>
          </list-item>
          <list-item>
            <p>A presentation of cough, dyspnea, pleuritic chest pain, blood-stained sputum, or sputum with brown mucus plugs.</p>
          </list-item>
          <list-item>
            <p>There are non-specific complaints like anorexia, fatigue,&#x000a0;generalized aches and pains, low-grade fever, and loss of weight.</p>
          </list-item>
          <list-item>
            <p>ABPA may occur with allergic fungal sinusitis having symptoms of chronic sinusitis with purulent sinus discharge.</p>
          </list-item>
        </list>
        <p>On physical examination:</p>
        <list list-type="bullet">
          <list-item>
            <p>In asthmatic patients with ABPA, wheezing, and/or rhonchi present on auscultation.</p>
          </list-item>
          <list-item>
            <p>In cystic fibrosis patients with ABPA, crepitations present on auscultation due to bronchiectasis.</p>
          </list-item>
          <list-item>
            <p>Tachypnea may present in case of asthma exacerbation or due to a secondary lung infection.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-66555.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>There is no individual test that establishes the diagnosis of allergic bronchopulmonary aspergillosis. The diagnosis is based on classic&#x000a0;clinical manifestations, radiographic findings, and immunological findings.<xref ref-type="bibr" rid="article-66555.r7">[7]</xref></p>
        <p>
<bold>Aspergillus skin test:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Aspergillus skin test (AST) is the investigation most commonly used for diagnosing sensitization to A. fumigatus.</p>
          </list-item>
          <list-item>
            <p>It reveals immediate cutaneous hypersensitivity to A. fumigatus.</p>
          </list-item>
          <list-item>
            <p>A positive Type I Hypersensitivity&#x000a0;reaction is typical of ABPA and represents the presence of A. fumigatus-specific IgE antibodies.</p>
          </list-item>
          <list-item>
            <p>Intradermal skin tests are more sensitive than the skin prick test for the diagnosis of Aspergillus sensitization.</p>
          </list-item>
        </list>
        <p>
<bold>Blood Abnormalities:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Elevated total serum IgE (usually over 1000 IU/mL)</p>
          </list-item>
          <list-item>
            <p>Elevated specific serum IgE to A. fumigatus (Af)</p>
          </list-item>
          <list-item>
            <p>Presence of serum precipitins (by gel diffusion) or raised specific serum IgG to A. fumigatus</p>
          </list-item>
          <list-item>
            <p>Peripheral blood eosinophilia (often absent, especially if the patient is on oral or inhaled corticosteroids)</p>
          </list-item>
        </list>
        <p><bold>Radiological manifestations of ABPA</bold>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chest X-ray has 50% sensitivity for the diagnosis of ABPA. It can show parenchymal infiltrate and bronchiectasis changes mostly in the upper lobes; however, all lobes may exhibit involvement.</p>
          </list-item>
          <list-item>
            <p>HRCT Chest is the investigation of choice to detect bronchiectasis distribution and other abnormalities that are undetectable on a chest X-ray, such as&#x000a0;centrilobular nodules and tree-in-bud appearance.</p>
          </list-item>
          <list-item>
            <p>Patients of ABPA with no abnormalities on HRCT chest are labeled as serologic ABPA (ABPA-S).</p>
          </list-item>
          <list-item>
            <p>Patients with central bronchiectasis on HRCT are labeled&#x000a0;as ABPA Central Bronchiectasis (ABPA-CB).</p>
          </list-item>
        </list>
        <p>The following shadows may present radiologically:</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x0201c;Finger in glove&#x0201d; opacity: suggestive of mucoid impaction in dilated bronchi.</p>
          </list-item>
          <list-item>
            <p>&#x0201c;Tramline shadows&#x0201d;: suggestive of parallel linear shadows extending from the hilum in bronchial distribution and reflecting longitudinal views of inflamed, edematous bronchi</p>
          </list-item>
          <list-item>
            <p>&#x0201c;Toothpaste shadows&#x0201d;: representing mucoid impaction of the bronchi</p>
          </list-item>
          <list-item>
            <p>&#x0201c;Ring shadows&#x0201d;: reflecting dilated bronchi with inflamed bronchial walls</p>
          </list-item>
        </list>
        <p>
<bold>Revised radiologic classification of allergic bronchopulmonary aspergillosis based on findings on a high-resolution computed tomography of the chest.</bold>
<xref ref-type="bibr" rid="article-66555.r12">[12]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>ABPA-S (Serological ABPA): Fulfills the diagnostic criteria of ABPA with an absence of any radiological finding of ABPA on HRCT of the thorax.</p>
          </list-item>
          <list-item>
            <p>ABPA-B&#x000a0;(Bronchiectasis ABPA): Satisfies the diagnostic requirements of ABPA along with the presence of bronchiectasis.</p>
          </list-item>
          <list-item>
            <p>ABPA-HAM (ABPA- High attenuation mucus): ABPA, along with the presence of high attenuation mucus on HRCT of the thorax.</p>
          </list-item>
          <list-item>
            <p>ABPA-CPF (ABPA-Chronic pleuropulmonary fibrosis): Fulfills the diagnostic criteria of ABPA with at least two radiological features suggestive of fibrosis (including fibrocavitary lesions, pulmonary fibrosis, pleural thickening) without the presence of mucoid impaction (or HAM).</p>
          </list-item>
        </list>
        <p><bold>Pulmonary function tests</bold>:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Aids in measuring&#x000a0;lung function impairment severity and monitoring improvement of lung function on follow up.</p>
          </list-item>
          <list-item>
            <p>Obstructive ventilatory defect: Stages I, III, IV, and often, V and may not correlate with the duration of ABPA or asthma.</p>
          </list-item>
          <list-item>
            <p>Patients with Stage V disease typically also have a restrictive ventilatory defect and a reduced DLCO.&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Bronchoscopy: </bold>Mucoid impaction may be evident, and bronchial brushings may reveal mucus that contains aggregates of eosinophils, fungal hyphae, and eosinophil-derived Charcot&#x02013;Leyden crystals. The finding of hyphae-filled mucus plugs is considered pathognomonic for ABPA.&#x000a0;BAL fluid analysis&#x000a0;from patients with ABPA: moderate eosinophilia (especially in steroid-naive patients) and increased levels of Aspergillus-specific IgE and IgA, but not IgG.</p>
        <p><bold>Sputum cultures for A. fumigatus:</bold> It is not diagnostic, but if it reveals an organism, then it helps in drug susceptibility test.</p>
        <p>The following criteria are used for the diagnosis and typing of ABPA.</p>
        <p><italic toggle="yes"><bold>1)&#x000a0;Rosenberg-Patterson criteria:</bold></italic>&#x000a0;It has eight major and three minor criteria.<xref ref-type="bibr" rid="article-66555.r13">[13]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold><italic toggle="yes">Major criteria</italic></bold>1. Asthma2. Presence of transient pulmonary infiltrates (fleeting shadows)3. Immediate cutaneous reactivity to&#x000a0;<italic toggle="yes">Af (A. fumigatus)</italic>4. Elevated total serum IgE5. Precipitating antibodies against&#x000a0;<italic toggle="yes">Af</italic>6. Peripheral blood eosinophilia7. Elevated serum IgE and IgG to&#x000a0;<italic toggle="yes">Af</italic>8. Central/proximal bronchiectasis with normal tapering of distal bronchi</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Minor criteria</bold>1. Expectoration of golden brownish sputum plugs2. Positive sputum culture for&#x000a0;<italic toggle="yes">Aspergillus</italic>&#x000a0;species3. Late (Arthus-type) skin reactivity to&#x000a0;<italic toggle="yes">Af&#x000a0;</italic></p>
          </list-item>
        </list>
        <p>
<bold>
<italic toggle="yes">2) Criteria proposed by ISHAM working group :</italic>
</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Predisposing conditions</bold>1. Bronchial asthma2. Cystic fibrosis</p>
          </list-item>
          <list-item>
            <p><bold><italic toggle="yes">Obligatory criteria (both should be present)</italic></bold>1. Type I - positive <italic toggle="yes">Aspergillus</italic>&#x000a0;skin test (immediate cutaneous hypersensitivity to&#x000a0;<italic toggle="yes">Aspergillus</italic>&#x000a0;antigen) or elevated IgE levels against&#x000a0;<italic toggle="yes">Af</italic>2. Elevated total IgE levels (greater than 1000 IU/mL)</p>
          </list-item>
          <list-item>
            <p><bold><italic toggle="yes">Other criteria (at least two of three)</italic></bold>1. Presence of precipitating or IgG antibodies against&#x000a0;<italic toggle="yes">Af</italic>&#x000a0;in serum2. Radiographic pulmonary opacities consistent with ABPA3. Total eosinophil count over 500 cells/microliter in steroid na&#x000ef;ve patients(If the patient meets all the other criteria, an IgE value less than 1000 IU/mL may be acceptable)</p>
          </list-item>
        </list>
        <p>Cystic Fibrosis Foundation has revised the criteria for the diagnosis of ABPA in patients with cystic fibrosis. ABPA is diagnosed and should be treated if the following are present:</p>
        <p>1. Deterioration of cough, wheeze, sputum, or deterioration in pulmonary functions</p>
        <p>2. Total serum IgE level more than 1000 IU/ml or greater than twofold from baseline</p>
        <p>3. Aspergillus precipitins or increased Aspergillus specific IgG or IgE</p>
        <p>4. New infiltrates on chest radiograph or CT scan</p>
        <p>If patients have new radiographic findings, symptoms, or an increase in baseline IgE to more than 500 IU/ml, even then treatment of ABPA should be given to cystic fibrosis patients.</p>
      </sec>
      <sec id="article-66555.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The main aim of the treatment of allergic bronchopulmonary aspergillosis is to control episodes of acute inflammation and to limit progressive lung injury.&#x000a0;</p>
        <p><bold>Goals of treatment:</bold>&#x000a0;</p>
        <p>&#x000a0; &#x02022; Controlling symptoms&#x000a0;&#x000a0;&#x02022; Preventing exacerbations&#x000a0;&#x000a0;&#x02022; Preserving normal lung function</p>
        <p>
<bold>Drugs used for the treatment of ABPA<xref ref-type="bibr" rid="article-66555.r7">[7]</xref>:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anti-inflammatory drugs: corticosteroids</p>
          </list-item>
          <list-item>
            <p>Antifungal drugs</p>
          </list-item>
          <list-item>
            <p>Anti IgE therapy</p>
          </list-item>
          <list-item>
            <p>Antibiotics</p>
          </list-item>
        </list>
        <p><bold>Corticosteroids:&#x000a0;</bold>Systemic corticosteroids are the primary therapy for ABPA. The steroids help to relieve the symptoms and decrease airflow obstruction, decrease serum IgE and reduce peripheral blood eosinophils. Moreover, there is a resolution of pulmonary inflammation, pulmonary infiltrates, and it prevents irreversible lung damage.</p>
        <list list-type="bullet">
          <list-item>
            <p>Prednisolone is a commonly used drug for treatment.</p>
          </list-item>
          <list-item>
            <p>Dose: 0.5 to 1 mg/kg a day for two weeks, followed by 0.5 mg/kg every other day for 6 to 8 weeks. A subsequent taper (by 5 to 10 mg every two weeks) over the 3 to 5 months. The duration of treatment depends upon the activity and severity of the disease. A low maintenance dose (5.0 to 7.5 mg/d) may be required long term to control the disease and prevent recurrence in some patients.</p>
          </list-item>
          <list-item>
            <p>IgE levels should be monitored within a few months of an acute episode or exacerbation and require followup every two months. Escalation of steroid therapy should be an option if IgE levels rise more than 100%.</p>
          </list-item>
          <list-item>
            <p>Inhaled corticosteroids&#x000a0;may help to&#x000a0;control of bronchospasm and may minimize the dose of systemic steroids.</p>
          </list-item>
          <list-item>
            <p>Stage 1 &#x00026; 3 requires oral/intravenous corticosteroids to control the acute stage and exacerbation.</p>
          </list-item>
          <list-item>
            <p>Stage 2 disease requires careful regular follow up.</p>
          </list-item>
          <list-item>
            <p>Stage 4 disease requires long-term steroids to control asthmatic symptoms and keep IgE levels at baseline.</p>
          </list-item>
          <list-item>
            <p>Stage 5 &#x00026; 6 disease requires long-term corticosteroid use.</p>
          </list-item>
        </list>
        <p><bold>Oral antifungal agents:</bold>&#x000a0;Antifungal agents act by decreasing the fungal load&#x000a0;that&#x000a0;reduces inflammatory activity and&#x000a0;act as steroid-sparing agents.&#x000a0;Antifungal therapy may help to decrease exacerbations.</p>
        <list list-type="bullet">
          <list-item>
            <p>Itraconazole is a commonly used drug for treatment.</p>
          </list-item>
          <list-item>
            <p>Itraconazole (200 mg twice daily for 16 weeks) leads to significant reductions in corticosteroid dose, decreases IgE levels, resolves&#x000a0;pulmonary infiltrates, improves&#x000a0;exercise tolerance, and improves pulmonary function.</p>
          </list-item>
          <list-item>
            <p>Itraconazole treatment (200 mg/d or every other day) is generally recommended for patients with ABPA who are steroid-dependent, have frequent relapses, and where benefits of treatment outweigh the risks.</p>
          </list-item>
          <list-item>
            <p>Other antifungal agents, including nystatin, amphotericin B, miconazole, clotrimazole, and natamycin, are generally ineffective in controlling ABPA. Ketoconazole may be effective, but hepatotoxicity limits its utility.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Newer antifungal drug: Voriconazole (300 to 600 mg/day) or posaconazole (800 mg/day) shows&#x000a0;clinical improvement with a reduction in the requirement of oral glucocorticoids, improvement in asthma control, and decline in IgE levels. Cost is a major current limitation; however, the high rate of efficacy shows that treatment with these agents as second-line therapy is justified in specific patients.<xref ref-type="bibr" rid="article-66555.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Nebulized lipid amphotericin B (AMB-L) requires further studies to determine efficacy; therefore, at this time,&#x000a0;it is not used for the treatment of ABPA.</p>
          </list-item>
        </list>
        <p><bold>Antibiotics:</bold> To prevent or treat an associated secondary bacterial infection.</p>
        <p><bold>Omalizumab:&#x000a0;</bold>An&#x000a0;anti-IgE recombinant humanized monoclonal antibody which prevents binding of IgE&#x000a0;to Fc-epsilon RI receptor on mast cells and basophils.</p>
        <list list-type="bullet">
          <list-item>
            <p>It is mainly used to treat&#x000a0;uncontrolled asthma on Step 4 GINA treatment guideline.</p>
          </list-item>
          <list-item>
            <p>Very expensive drug.</p>
          </list-item>
          <list-item>
            <p>According to various studies and cases, it is a good alternate option in patients of ABPA with CF in whom steroid dependency and with contraindications to steroids. It also has a steroid-sparing effect and decreases systemic inflammatory markers.<xref ref-type="bibr" rid="article-66555.r15">[15]</xref><xref ref-type="bibr" rid="article-66555.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Dosage:&#x000a0;375mg SC injection every two weeks for at least 4 to 6 months. The dosage depends upon the serum total IgE level. In ABPA, despite a high level of IgE, the routine dose of omalizumab is sufficient.<xref ref-type="bibr" rid="article-66555.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Supportive measures:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Airway clearance treatment to ABPA-related bronchiectasis patients should be prescribed nebulization with hypertonic saline with salbutamol and mucus clearance valves or percussion vests.</p>
          </list-item>
          <list-item>
            <p>Avoid areas and environmental conditions with high mold counts, such as decomposing organic materials and moldy indoor environments.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-66555.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>
<bold>Differential Diagnosis of allergic bronchopulmonary aspergillosis<xref ref-type="bibr" rid="article-66555.r18">[18]</xref>:</bold>
</p>
        <p>ABPA mimics many diseases that involve both airway and lung parenchyma. Undiagnosed lung infiltrates, pneumonia, bronchiectasis make a long list of differential diagnoses. Following are few diseases which should be carefully ruled out while making a diagnosis of ABPA:</p>
        <list list-type="bullet">
          <list-item>
            <p>Corticosteroid-dependent asthma without ABPA</p>
          </list-item>
          <list-item>
            <p>Severe asthma with fungal sensitivity (SAFS)</p>
          </list-item>
          <list-item>
            <p>Cystic fibrosis (CF)</p>
          </list-item>
          <list-item>
            <p>Bronchiectasis</p>
          </list-item>
          <list-item>
            <p>Chronic necrotizing aspergillosis</p>
          </list-item>
          <list-item>
            <p>Chronic eosinophilic pneumonia</p>
          </list-item>
          <list-item>
            <p>Chronic obstructive pulmonary disease (COPD)</p>
          </list-item>
          <list-item>
            <p>Churg&#x02013;Strauss syndrome</p>
          </list-item>
          <list-item>
            <p>Bronchocentric granulomatosis</p>
          </list-item>
          <list-item>
            <p>Acute eosinophilic pneumonia (including drug-induced pneumonitis)</p>
          </list-item>
          <list-item>
            <p>Pulmonary tuberculosis</p>
          </list-item>
          <list-item>
            <p>Parasitic infections</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity pneumonitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-66555.s11" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p><bold>Itraconazole </bold>interferes with the hepatic metabolism of several medications, including cyclosporine, oral hypoglycemics, tacrolimus, terfenadine, cisapride, and midazolam. Deranged liver function test results, rash, headache, edema, nausea, vomiting, and diarrhea are the most common side effects. Impaired absorption is most significant with proton pump inhibitors.<xref ref-type="bibr" rid="article-66555.r19">[19]</xref></p>
        <p><bold>Glucocorticoids side effects:</bold>&#x000a0;Weight gain, osteopenia, acne, skin atrophy, diabetes mellitus, glaucoma, cataracts, avascular necrosis of bone, infection, hypertension, and growth retardation in children.</p>
        <p><bold>Omalizumab side effects:&#x000a0;</bold>The most common reaction is swelling and redness at the injection site. Anaphylaxis may occur in asthmatics.</p>
      </sec>
      <sec id="article-66555.s12" sec-type="Staging">
        <title>Staging</title>
        <p>
<bold>New Proposed clinical staging of allergic bronchopulmonary aspergillosis in asthmatic patients<xref ref-type="bibr" rid="article-66555.r7">[7]</xref>:</bold>
</p>
        <p>
<italic toggle="yes">Stage 0: Asymptomatic</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>No previous diagnosis of ABPA</p>
          </list-item>
          <list-item>
            <p>Controlled asthma (according to GINA/EPR-3 guidelines)</p>
          </list-item>
          <list-item>
            <p>Fulfilling the diagnostic criteria of ABPA (ISHAM working group criteria)</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Stage 1:&#x000a0; Acute</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>No previous diagnosis of ABPA</p>
          </list-item>
          <list-item>
            <p>Uncontrolled asthma/symptoms consistent with ABPA</p>
          </list-item>
          <list-item>
            <p>Meeting the diagnostic criteria of ABPA
<list list-type="bullet"><list-item><p>1a: With mucoid impaction - Mucoid impaction observed on chest imaging or bronchoscopy</p></list-item><list-item><p>1b: Without mucoid impaction - Absence of mucoid impaction on chest imaging or bronchoscopy</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Stage 2:&#x000a0; Response</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinical and/or radiological improvement and</p>
          </list-item>
          <list-item>
            <p>Decline in IgE by greater than or equal to 25% of baseline at 8 weeks</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Stage 3:&#x000a0; Exacerbation</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinical and/or radiological worsening and</p>
          </list-item>
          <list-item>
            <p>Increase in IgE by &#x02265; 50% from the baseline established during response/remission</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Stage 4:&#x000a0; Remission</italic>
</p>
        <p>Sustained clinical-radiological improvement and</p>
        <list list-type="bullet">
          <list-item>
            <p>IgE levels persisting at or below baseline (or increase by less than 50%) for greater than or equal to 6 months off treatment</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Stage 5a:&#x000a0; Treatment-dependent ABPA</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Greater than or equal to two exacerbations within six months of stopping therapy or</p>
          </list-item>
          <list-item>
            <p>Worsening of clinical and/or radiological condition, along with immunological worsening (rise in IgE levels) on tapering oral steroids/azoles</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Stage 5b:&#x000a0; Glucocorticoid-dependent asthma</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Systemic glucocorticoids required for control of asthma while the ABPA activity is controlled (as indicated by IgE levels and thoracic imaging)</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Stage 6:&#x000a0; Advanced ABPA</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Extensive bronchiectasis due to ABPA on chest imaging and</p>
          </list-item>
          <list-item>
            <p>Complications (cor pulmonale and/or chronic type II respiratory failure)</p>
          </list-item>
        </list>
        <p>EPR-3: third expert panel report; GINA: global initiative against asthma.</p>
      </sec>
      <sec id="article-66555.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The natural history, progression, remission, and recurrences of ABPA are not well understood. Patients without central bronchiectasis at the time of diagnosis tend to maintain their lung function despite occasional exacerbations.<xref ref-type="bibr" rid="article-66555.r20">[20]</xref>&#x000a0;With appropriate treatment, long-term control of ABPA is feasible, and durable remissions are common.</p>
        <p>Treatment of Stage 1 disease using corticosteroids typically results in decreased sputum production, improved control of bronchospasm, over 35% reduction in total IgE within 8 weeks, clearing of precipitating antibodies, and resolution of radiographic infiltrates. IgE levels typically do not completely normalize, but&#x000a0;it decreases by approximately one-half of peak levels seen in the acute stage.</p>
        <p>Progression of Stage 5 disease to pulmonary fibrosis may be preventable if patients maintain therapy on low-dose steroids. Persons with an FEV1 persistently under 0.8 L have a worse prognosis.</p>
      </sec>
      <sec id="article-66555.s14" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of allergic bronchopulmonary aspergillosis include<xref ref-type="bibr" rid="article-66555.r21">[21]</xref><xref ref-type="bibr" rid="article-66555.r22">[22]</xref><xref ref-type="bibr" rid="article-66555.r23">[23]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Recurrent asthma exacerbations and steroid dependence</p>
          </list-item>
          <list-item>
            <p>Aspergilloma</p>
          </list-item>
          <list-item>
            <p>Invasive aspergillosis</p>
          </list-item>
          <list-item>
            <p>Chronic pulmonary aspergillosis</p>
          </list-item>
          <list-item>
            <p>Cavitation</p>
          </list-item>
          <list-item>
            <p>Local emphysema</p>
          </list-item>
          <list-item>
            <p>Chronic or recurrent lobar atelectasis</p>
          </list-item>
          <list-item>
            <p>Honeycomb fibrosis</p>
          </list-item>
          <list-item>
            <p>Complications related to bronchiectasis like hemoptysis, recurrent pulmonary infection</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-66555.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with allergic bronchopulmonary aspergillosis have to be more conscious about the worsening of their symptoms. If the worsening of respiratory symptoms occurs on treatment or new respiratory symptoms develops on stage 2 and stage 3, then immediately consult a pulmonologist.</p>
        <p>Patients with ABPA-CB have a higher chance&#x000a0;of getting a secondary infection and complications related to bronchiectasis. If fever or hemoptysis occurs, then immediately consult a pulmonologist.</p>
        <p>If a patient is receiving long-term oral corticosteroids, all adverse drug effects should be properly understood. Screening should be performed for corticosteroid adverse effects of osteoporosis/osteopenia (by bone density measurement) and cataracts (by eye exams) regularly.<xref ref-type="bibr" rid="article-66555.r24">[24]</xref></p>
        <p>Patients bronchiectasis should receive training on sputum clearance techniques. Recommendations are for influenza and pneumococcal immunizations.<xref ref-type="bibr" rid="article-66555.r24">[24]</xref></p>
        <p>Avoid areas and environmental conditions with high mold counts, such as decomposing organic materials, and moldy indoor environments.</p>
      </sec>
      <sec id="article-66555.s16" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="order">
          <list-item>
            <p>All patients with asthma and CF, regardless of the severity of the level of control, should routinely have screening for ABPA using A. fumigatus-specific IgE levels.</p>
          </list-item>
          <list-item>
            <p>Glucocorticoids should be the first-line of therapy in ABPA, and itraconazole reserved for those with exacerbations and glucocorticoid-dependent disease.</p>
          </list-item>
          <list-item>
            <p>Establishing IgE sensitization to <italic toggle="yes">Aspergillus</italic> through either skin prick test or measurement of specific serum IgE is a reasonable first step in an asthmatic being evaluated for ABPA. The inability to establish IgE sensitization to&#x000a0;<italic toggle="yes">Aspergillus</italic>&#x000a0;virtually excludes ABPA from consideration. If skin testing&#x000a0;and/or&#x000a0;specific IgE are positive, then a total serum IgE, precipitins to&#x000a0;<italic toggle="yes">Aspergillus,&#x000a0;</italic>and an eosinophil count should be assayed. Furthermore, chest imaging, preferably with a high-resolution chest CT, is necessary as well.</p>
          </list-item>
          <list-item>
            <p>Early detection and treatment can prevent the development of bronchiectasis or pulmonary fibrosis that otherwise occurs in the later stages of the disease.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-66555.s17" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Allergic bronchopulmonary aspergillosis is a fungal infection of the lung secondary to a hypersensitivity reaction to antigens of <italic toggle="yes">Aspergillus fumigatus</italic>. This disease process is uncommon; however, routine screening is necessary for asthmatic and cystic fibrosis patients. The interprofessional approach of pulmonologists, infectious diseases, primary care physicians, pharmacists, and other healthcare professionals is essential to educate and improve patient outcomes. [Level V] A focused history and physical examination along with appropriate imaging with a high-resolution chest tomography of the chest are critical to establish an early diagnosis and initiate early treatment to prevent the development of bronchiectasis or pulmonary fibrosis. As targeted immunotherapy is evolving, there may be new treatment options in the near future.&#x000a0;</p>
        <p>The nurse place an important role in monitoring the patient for progression or worsening symptoms that must be reported back to the interprofessional team leader. As drug therapy and monitoring are complex in these patients, a pharmacist should evaluate for drug-drug interactions and coordinate drug therapy, assisting in monitoring for compliance and side effects and reporting to the clinical team leader if untoward complications arise. The nurse practitioner, a physician assistant, must coordinate care and patient and family education together so that they are aware of the need to monitor treatment, follow up regularly, and return for reassessment if unexpected complications occur. This disease is challenging to treat, and only through coordinated interprofessional care will the best outcomes be achieved. [Level V]</p>
      </sec>
      <sec id="article-66555.s18">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=66555&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=66555">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/lung-disease-respiratory-health/allergic-bronchopulmonary-aspergillosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=66555">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/66555/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=66555">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-66555.s19">
        <fig id="article-66555.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Chronic Obstructive Pulmonary Disease, Allergic Bronchopulmonary Aspergillosis. This image shows a posterior-anterior&#x000a0;view of a patient with COPD and ABPA. Contributed by H Shulman, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="abpa1pajpg" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-66555.s20">
        <fig id="article-66555.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Chronic Obstructive Pulmonary Disease, Allergic Bronchopulmonary Aspergillosis, CT Scan Contributed by H Shulman, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="abpa1ct" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-66555.s21">
        <fig id="article-66555.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Allergic Bronchopulmonary Aspergillosis Contributed by S Bhimji, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="allergic__bronchopulmonary__asp" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-66555.s22">
        <title>References</title>
        <ref id="article-66555.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oguma</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shimoda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kamei</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsuse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hebisawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takayanagi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Konno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fukunaga</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tomomatsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Asano</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Allergic bronchopulmonary aspergillosis in Japan: A nationwide survey.</article-title>
            <source>Allergol Int</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-84</page-range>
            <pub-id pub-id-type="pmid">28546015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sehgal</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Choudhary</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dhooria</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Behera</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chakrabarti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of sensitization to Aspergillus flavus in patients with allergic bronchopulmonary aspergillosis.</article-title>
            <source>Med Mycol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>270</fpage>
            <page-range>270-276</page-range>
            <pub-id pub-id-type="pmid">29566248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vitte</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ranque</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carsin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Romain</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cassagne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gouitaa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baravalle-Einaudi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bel</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Reynaud-Gaubert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dubus</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>M&#x000e8;ge</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gaudart</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Multivariate Analysis As a Support for Diagnostic Flowcharts in Allergic Bronchopulmonary Aspergillosis: A Proof-of-Concept Study.</article-title>
            <source>Front Immunol</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>1019</fpage>
            <pub-id pub-id-type="pmid">28878778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chauhan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Santiago</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kirschmann</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Hauptfeld</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Knutsen</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Hutcheson</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Woulfe</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Slavin</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Bellone</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>The association of HLA-DR alleles and T cell activation with allergic bronchopulmonary aspergillosis.</article-title>
            <source>J Immunol</source>
            <year>1997</year>
            <month>Oct</month>
            <day>15</day>
            <volume>159</volume>
            <issue>8</issue>
            <fpage>4072</fpage>
            <page-range>4072-6</page-range>
            <pub-id pub-id-type="pmid">9378997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chauhan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Santiago</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hutcheson</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Spitznagel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Slavin</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Bellone</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>106</volume>
            <issue>4</issue>
            <fpage>723</fpage>
            <page-range>723-9</page-range>
            <pub-id pub-id-type="pmid">11031343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhankhur</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Singla</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chander</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of allergic bronchopulmonary aspergillosis among patients with severe bronchial asthma in a tertiary care hospital in Northern India.</article-title>
            <source>Indian J Pathol Microbiol</source>
            <year>2019</year>
            <season>Jan-Mar</season>
            <volume>62</volume>
            <issue>1</issue>
            <fpage>111</fpage>
            <page-range>111-113</page-range>
            <pub-id pub-id-type="pmid">30706871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sehgal</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Dhooria</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis.</article-title>
            <source>Expert Rev Respir Med</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>1317</fpage>
            <page-range>1317-1334</page-range>
            <pub-id pub-id-type="pmid">27744712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gago</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Denning</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Bowyer</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiological aspects of Aspergillus colonization in disease.</article-title>
            <source>Med Mycol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>57</volume>
            <issue>Supplement_2</issue>
            <fpage>S219</fpage>
            <page-range>S219-S227</page-range>
            <pub-id pub-id-type="pmid">30239804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stevens</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Kurup</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Knutsen</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Greenberger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Judson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Denning</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Crameri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brody</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Light</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Skov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maish</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mastella</surname>
                <given-names>G</given-names>
              </name>
              <collab>Participants in the Cystic Fibrosis Foundation Consensus Conference</collab>
            </person-group>
            <article-title>Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference.</article-title>
            <source>Clin Infect Dis</source>
            <year>2003</year>
            <month>Oct</month>
            <day>01</day>
            <volume>37 Suppl 3</volume>
            <fpage>S225</fpage>
            <page-range>S225-64</page-range>
            <pub-id pub-id-type="pmid">12975753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenberger</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liotta</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Analysis of bronchoalveolar lavage in allergic bronchopulmonary aspergillosis: divergent responses of antigen-specific antibodies and total IgE.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>1988</year>
            <month>Aug</month>
            <volume>82</volume>
            <issue>2</issue>
            <fpage>164</fpage>
            <page-range>164-70</page-range>
            <pub-id pub-id-type="pmid">3042837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kauffman</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Tomee</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>van der Werf</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>de Monchy</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Ko&#x000eb;ter</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Review of fungus-induced asthmatic reactions.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>1995</year>
            <month>Jun</month>
            <volume>151</volume>
            <issue>6</issue>
            <fpage>2109</fpage>
            <page-range>2109-15; discussion 2116</page-range>
            <pub-id pub-id-type="pmid">7767565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Saxena</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Chakrabarti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>An alternate method of classifying allergic bronchopulmonary aspergillosis based on high-attenuation mucus.</article-title>
            <source>PLoS One</source>
            <year>2010</year>
            <month>Dec</month>
            <day>15</day>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>e15346</fpage>
            <pub-id pub-id-type="pmid">21179536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Panjabi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Allergic Bronchopulmonary Aspergillosis: A Perplexing Clinical Entity.</article-title>
            <source>Allergy Asthma Immunol Res</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>282</fpage>
            <page-range>282-97</page-range>
            <pub-id pub-id-type="pmid">27126721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chishimba</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Niven</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Cooley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Denning</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.</article-title>
            <source>J Asthma</source>
            <year>2012</year>
            <month>May</month>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>423</fpage>
            <page-range>423-33</page-range>
            <pub-id pub-id-type="pmid">22380765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nov&#x000e9;-Josserand</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Auzou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reix</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Murris-Espin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Br&#x000e9;mont</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mammar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mely</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hubert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Durieu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Burgel</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients.</article-title>
            <source>Pediatr Pulmonol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>190</fpage>
            <page-range>190-197</page-range>
            <pub-id pub-id-type="pmid">27717223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collins</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Devos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hudes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rosenstreich</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab.</article-title>
            <source>J Asthma Allergy</source>
            <year>2012</year>
            <volume>5</volume>
            <fpage>65</fpage>
            <page-range>65-70</page-range>
            <pub-id pub-id-type="pmid">23204847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voskamp</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Gillman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Symons</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sandrini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rolland</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>O'Hehir</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Douglass</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2015</year>
            <season>Mar-Apr</season>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>192</fpage>
            <page-range>192-9</page-range>
            <pub-id pub-id-type="pmid">25640470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenberger</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Clinical aspects of allergic bronchopulmonary aspergillosis.</article-title>
            <source>Front Biosci</source>
            <year>2003</year>
            <month>Jan</month>
            <day>01</day>
            <volume>8</volume>
            <fpage>s119</fpage>
            <page-range>s119-27</page-range>
            <pub-id pub-id-type="pmid">12456338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaruratanasirikul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sriwiriyajan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effect of omeprazole on the pharmacokinetics of itraconazole.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-61</page-range>
            <pub-id pub-id-type="pmid">9626921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vlahakis</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Aksamit</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of allergic bronchopulmonary aspergillosis.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>76</volume>
            <issue>9</issue>
            <fpage>930</fpage>
            <page-range>930-8</page-range>
            <pub-id pub-id-type="pmid">11560305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Allergic bronchopulmonary aspergillosis.</article-title>
            <source>Chest</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>135</volume>
            <issue>3</issue>
            <fpage>805</fpage>
            <page-range>805-826</page-range>
            <pub-id pub-id-type="pmid">19265090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maturu</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Acute Invasive Pulmonary Aspergillosis Complicating Allergic Bronchopulmonary Aspergillosis: Case Report and Systematic Review.</article-title>
            <source>Mycopathologia</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>180</volume>
            <issue>3-4</issue>
            <fpage>209</fpage>
            <page-range>209-15</page-range>
            <pub-id pub-id-type="pmid">26045286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lowes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chishimba</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Greaves</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Denning</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Development of chronic pulmonary aspergillosis in adult asthmatics with ABPA.</article-title>
            <source>Respir Med</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>109</volume>
            <issue>12</issue>
            <fpage>1509</fpage>
            <page-range>1509-15</page-range>
            <pub-id pub-id-type="pmid">26507434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66555.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibson</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Allergic bronchopulmonary aspergillosis.</article-title>
            <source>Semin Respir Crit Care Med</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>185</fpage>
            <page-range>185-91</page-range>
            <pub-id pub-id-type="pmid">16612769</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
